Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.39 |
| ▸ | RELA | Q04206 | 5/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072993 | 0.83 | NFKB1 (0.40) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL21838549 | 0.83 | NFKB1 (0.40) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL20063683 | 0.82 | POLB (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL20072764 | 0.81 | NFKB1 (0.38) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL20072766 | 0.80 | NFKB1 (0.36) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL20072839 | 0.80 | HDAC4 (0.41) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL20063770 | 0.78 | HDAC4 (0.37) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL20073036 | 0.77 | CHRNA7 (0.37) | NFKB1NFKB2RELAKDM1AHDAC4 | |
| SCHEMBL20063844 | 0.77 | CHRNA7 (0.37) | NFKB1NFKB2RELAKDM1AHDAC4 | |
| SCHEMBL31620129 | 0.76 | BTK (0.48) | BTKNFKB1NFKB2RELAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | BTK 647/4885NFKB1 367/4885NFKB2 1669/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | BTK 647/4885NFKB1 367/4885NFKB2 1669/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | BTK 645/4885NFKB1 355/4885NFKB2 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.